Two US patents shielding Impax’ Zomig (zolmitriptan) nasal spray are not invalid, a US Court of Appeals has affirmed, upholding an unfavourable lower court ruling against abbreviated new drug application (ANDA) filer Lannett.
The US player had appealed against Delaware District Judge Richard Andrews’ finding that US formulation patents 6,750,237 and 7,220,767 were...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?